Podcasts about medtronic inc

Deepthy Varghese, MSN, ACNP, FNP, Northside Hospital is joined by Hung-Fat Tse, Sr., MD, University of Hong Kong and Glenn Young, MBBS, Royal Adelaide Hospital to discuss the effectiveness of the PRECISE-DAPT score with the CHA2DS2VASC score in predicting thromboembolic risk in nonvalvular atrial fibrillation (AF) patients undergoing transesophageal echocardiography (TEE) before AF ablation. 428 patients were analyzed, with 60 in the thrombogenic positive group and 368 in the thrombogenic milieu negative group. Multivariate logistic regression revealed that the PRECISE-DAPT score independently predicted thrombogenic milieu presence (OR: 1.145, CI: 1.083–1.211, p < 0.001). The study concluded that the PRECISE-DAPT score is a valuable predictor of thromboembolic risk in AF patients undergoing TEE before ablation procedures.   https://www.hrsonline.org/education/TheLead https://jafib-ep.com/journal/february-2024-volume-17-issue-1/original-research-the-predictive-value-of-precise-dapt-scores-for-thrombogenic-milieu-of-the-left-atrium-in-patients-awaiting-af-ablation/   Host Disclosure(s): D. Varghese: Nothing to disclose   Contributor Disclosure(s): H. Tse: Research: Abbott Medical, Medtronic Inc., Boston Scientific, AstraZeneca, Daiichi Sankyo, Pfizer/BMS, Amgen, Bayer Healthcare Pharmaceuticals, Sanofi, Conoraria/Speaking/Teaching: Abbott Medical, Medtronic Inc., Boston Scientific, AstraZeneca, Daiichi Sankyo, Pfizer/BMS, Amgen, Bayer Healthcare Pharmaceuticals, Sanofi, Boehringer Ingelheim, Biotronik G. Young: Nothing to disclose This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365     https://www.heartrhythm365.org/URL/TheLeadEpisode72

Vascular Solutions LLC v. Medtronic, Inc.

Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by guest Christine M. Albert, MD, MPH, FHRS, Cedars-Sinai Medical Center and Marina Cerrone, MD, NYU School of Medicine to discuss how Electrocardiogram (ECG) abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD), but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD. https://www.hrsonline.org/education/TheLead https://pubmed.ncbi.nlm.nih.gov/37956651/ Host Disclosure(s): J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association Contributor Disclosure(s): C. Albert: Research: Abbott, Roche Diagnostics, St. Jude Medical, NIH, Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Element Services, Inc., Illumina, Novartis M. Cerrone: Research: American Heart Association, Honoraria/Speaking/Consulting: StrideBio, Medtronic Inc., BioMarin, Inc., Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode55

Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcastHere are the highlights: Belzutifan (Welireg) for RCC: - FDA approved belzutifan (Welireg) for advanced renal cell carcinoma (RCC) following prior treatments with PD-1/PD-L1 inhibitors and VEGF-TKI. Belzutifan is an HIF-2α inhibitor, the first novel therapeutic class for advanced RCC since 2015. Approval based on phase 3 LITESPARK-005 study data, granted to Merck Inc. Pulse Field Ablation (PFA) system for AFib: - FDA approved PulseSelect PFA system for atrial fibrillation (Afib) treatment. PFA uses electrical pulses to ablate cardiac tissue without thermal energy, reducing adverse events. Medtronic Inc. received approval. Roflumilast 0.3% (Zoryve) for Seborrheic Dermatitis: - FDA approved roflumilast foam 0.3% (Zoryve) for seborrheic dermatitis in individuals aged 9 and older. This is the first drug with a new mechanism of action for seborrheic dermatitis in over two decades. Approval supported by positive results from the STRATUM phase 3 trial, granted to Arcutis Biotherapeutics, Inc. Eflornithine (Iwilfin) for Neuroblastoma: - FDA approved eflornithine (Iwilfin) to reduce the risk of relapse in high-risk neuroblastoma patients. Eflornithine inhibits ornithine decarboxylase, reducing cell growth. Approval based on multi-site study results and granted to US WorldMeds, LLC. Isavuconazonium Sulfate For Pediatric Patients: - FDA approved isavuconazonium sulfate (Cresemba) for invasive aspergillosis and mucormycosis in pediatric patients. Provides an alternative to eye drops for glaucoma treatment, offering continuous delivery of travoprost. Approval based on Phase 3 trials and plans for label change, granted to Glaukos. Augmented Reality Smart Glasses Technology: - FDA approved NuLoupes augmented reality smart glasses with 3D stereoscopic imaging for dentistry and medicine. Offers live 3D stereoscopic imaging and plans to ship developer kits in 2024. Approval granted to NuEyes. OneRF Ablation System for Parkinson's: - FDA cleared the OneRF Ablation System for neurosurgical procedures in Parkinson's disease and other neurological conditions. Designed to capture electrical activity and selectively destroy brain tissue. Launch planned by NeuroOne in the first half of 2024. Pimicotinib For Tenosynovial Giant Cell Tumor: - FDA granted fast track approval to pimicotinib for the treatment of tenosynovial giant cell tumors. Demonstrated an overall response rate of 87.5% in a Phase 1b trial. Manufactured by Abbisko and commercialized in partnership with Merck. NDA for MDMA-Assisted Therapy for PTSD: - NDA submitted for MDMA in combination with psychotherapy for PTSD, aiming to be the first psychedelic-assisted therapy approved for PTSD. Submission by MAPS Public Benefit Corporation based on positive Phase 3 clinical trial results. Requested Priority Review of the NDA.

Chronic pain can be incredibly challenging -- for patients, of course, and also for their physicians. On this episode of ANA investigates, Dr. Adeline Goss talks to Dr. Prasad Shirvalkar of UCSF about a new possible strategy for treating chronic pain: deep brain stimulation. Series 5, Episode 2 Featuring: Guest: Dr. Prasad Shirvalkar of UCSF Interviewer: Dr. Adeline Goss Disclosures: Dr. Shirvalkar disclosed that Medtronic Inc, donated devices for research, but no direct financial support

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College discusses Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death with Sei Iwai, MD, FHRS, of WMC Health Network, and Rachel Lampert, MD, FHRS, of Yale University School of Medicine. This study reports on cardiac events in elite athletes with genetic heart diseases associated with sudden cardiac death that, through a shared decision making process have returned to play. This was done under the care of expert sports and genetic cardiologists. The incidence of cardiac events was low and no fatalities occurred. https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacc.2023.05.059  Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D   Contributor Disclosure(s): S. Iwai: No relevant financial relationships with ineligible companies to disclose. R. Lampert: Honoraria/Speaking/Consulting Fee: Medtronic; Research (Contracted Grants for PIs Named Investigators Only): MediLynx, Medtronic, Boston Scientific, Medtronic Inc.

Medtronic, Inc. v. Teleflex Life Sciences Limited

Medtronic, Inc. v. Teleflex Life Sciences Limited

Jason T. Jacobson, MD, FHRS, is joined by guests Laurent Macle, MD, FHRS, and Peter M. Kistler, MBBS, PhD, FHRS, for a discussion of the Improved PAF Trial. Prior studies have demonstrated clinical benefits associated with cryoballoon pulmonary vein isolation (PVI) and concomitant posterior wall isolation (PWI) in patients with persistent atrial fibrillation (AF). However, the role for this approach in patients with paroxysmal atrial fibrillation (PAF) remains unclear. Compared with cryoballoon PVI, cryoballoon PVI+PWI appears to be associated with greater freedom from recurrent atrial arrhythmias and AF in patients with PAF during long-term follow-up >3 years. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Aboot, Phillips; Stocks (Privately Held): Atlas 5D   Contributor Disclosure(s): L. Macle: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Abbott Medical, Bristol-Myers Squibb, Servier, Medtronic Inc., Pfizer, Inc. P. Kistler: Honoraria/Speaking/Consulting Fee: Abbott/Abbott Medical  

Axonics, Inc. v. Medtronic, Inc.

Axonics, Inc. v. Medtronic, Inc.

Axonics, Inc. v. Medtronic, Inc.

Medtronic, Inc. v. Teleflex Innovations S.A.R.L.

Medtronic, Inc. v. Teleflex Innovations S.A.R.L.

Medtronic, Inc. v. Teleflex Innovations S.A.R.L.

Atrial fibrillation may reach pandemic proportions in the next 2-3 decades. Factors that drive this phenomenon have been studied in predominantly White populations, leading to a significant underrepresentation of certain racial/ethnic groups in atrial fibrillation epidemiological studies. Most atrial fibrillation epidemiology studies suggest that the non-Hispanic Black population has a lower incidence/prevalence of atrial fibrillation, despite a higher risk factor burden (“Afib paradox”). At the same time, non-Hispanic Blacks have worse outcomes compared to the White population and underrepresented populations and women are less likely than White men to receive optimal guideline-based therapies for atrial fibrillation. In this episode, CardioNerds Dr. Kelly Arps (Co-Chair Atrial Fibrillation series, Cardiology fellow at Duke University), Dr. Colin Blumenthal (Co-Chair Atrial Fibrillation series, CardioNerds Academy House Faculty Leader for House Jones, Cardiology fellow at the University of Pennsylvania), and Dr. Dinu-Valentin Balanescu (CardioNerds Academy Faculty for House Jones, rising internal medicine chief resident at Beaumont Hospital), discuss with Dr. Larry Jackson (cardiac electrophysiologist and Vice Chief of Diversity, Equity, and Inclusion in the Division of Cardiology at Duke University) about atrial fibrillation epidemiology and health equity, challenges and possible solutions to improving diversity in clinical trials, and race/ethnicity/sex/gender differences in the detection, management, and outcomes of atrial fibrillation. Audio editing by CardioNerds Academy Intern, student doctor Akiva Rosenzveig. This CardioNerds Atrial Fibrillation series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Kelly Arps and Dr. Colin Blumenthal. This series is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. We have collaborated with VCU Health to provide CME. Claim free CME here! Disclosure: Larry R. Jackson II, MD, MHs, has the following relevant financial relationships:Advisor or consultant for: Biosense Webster Inc.Speaker or a member of a speakers bureau for: Biotronik Inc.; Medtronic Inc. Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Atrial Fibrillation: Epidemiology, Health Equity, & The Double Paradox Atrial fibrillation confers an enormous public health burden. It is estimated that it will reach pandemic proportions over the next 30 years, with potentially 100-180 million people worldwide suffering from this condition.Large epidemiological atrial fibrillation registries have very small populations of underrepresented groups. More diverse enrollment in clinical trials is essential and may be obtained by increasing diversity among research staff, principal investigators, and steering committees, and use of mobile/telehealth technologies to remove bias related to differences in presentation. The CardioNerds Clinical Trials Network specifically aims pair equitable trial enrollment with trainee personal and professional development.Most atrial fibrillation epidemiology studies suggest that the non-Hispanic Black population has lower incidence/prevalence of atrial fibrillation, despite higher risk factor burden. This “paradox” is likely due to a multifactorial process, with clinical differences, socioeconomic factors, and genetic factors contributing.Underrepresented populations are less likely than White patients to receive optimal guideline-based management of atrial fibrillation.

Episode 45: Osteoporosis Update. Dr Linares (endocrinologist) explains the basics of screening and treatment of osteoporosis, referring frequently to the updated guidelines of osteoporosis by AACE and ACE (2020). A new group of residents is introduced. Congratulations to our new group of residents:  Amelia Martinez Lopez, Amardeep Singh Chetha, Cecilia Selena Covenas, Funmilayo Helen Idemudia, Licet Imbert Matos, Su Myat Hlaing, Timiiye Dawn Yomi, and Young Na Sung. This group of residents will start in July 2021 and will graduate in July 2024. We hope you enjoy your time with us.Today is March 22, 2021.Implanted pacemakers and defibrillators are equipped with a switch that responds to magnetic forces to stop them when needed. Magnetic interference between these cardiac implantable electronic devices (CIEDs) and mobile devices have been investigated for years. It has been established that magnetic fields stronger than 10 gauss can deactivate these cardiac devices, causing pacemakers to give asynchronous pacing and ICDs to stop tachyarrhythmia detection.The Heart Rhythm Society journal, published in October 2009 (that was 11 years ago), an association between portable headphones and significant electromagnetic interference (EMI) in patients with implantable cardioverter-defibrillators (ICD) and pacemakers (PM). 100 patients with implanted devices were tested with different portable headphones. Headphones effectively deactivated implanted devices when held less than 2 cm from skin on the left side of chest. There was not interference when headphones were placed farther than 3 cm. In this study, normal functioning of the devices was restored in 29 out of 30 cases when the headphones were removed from the patient’s chest. The recommendation from that study was to recommend patients to keep their portable headphones at least 3 cm away from their implanted device.More recently, in January 2021, the same journal posted the effect of iPhone 12 on ICDs deactivation. iPhone 12 and MagSafe technology, which allows faster wireless charging, contain strong magnets. iPhone 12 successfully deactivated a Medtronic Inc. ICD when tested by a group of investigators in a patient[2]. The official Apple Support website posted on February 25, 2021, “To avoid any potential interactions with these devices, keep your iPhone and MagSafe accessories a safe distance away from your device (more than 6 inches / 15 cm apart or more than 12 inches / 30 cm apart if wirelessly charging)”[3]. Other devices such as fitness tracker wristbands, and even e-cigarettes have been involved in deactivation of ICDs.Bottom line: Make sure your patient discusses with you or their cardiologist before buying wearable or mobile technology that may interfere with their implanted cardiovascular devices.This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it’s sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. “The secret of getting ahead is getting started” —Mark Twain.Osteoporosis UpdateDuring this conversation, we discussed some parts of the guidelines from the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE)[2], updated in 2020. This is not a complete analysis of those guidelines. For a comprehensive explanation of the guidelines, visit the AACE or ACE websites. The recommendations from these organizations may be different than the ones given by the American Academy of Family Physicians (AAFP) or the United States Preventive Services Taskforce (USPSTF), which are organizations we are more familiar with as family physicians.The questions analyzed during this conversation includes:When would you consider a DEXA scan to screen a woman younger than 65 for osteoporosis? What to do when the report says Osteopenia (T score -1.0 to -2.5)? Let’s mention the recommended dose of Vitamin D and Calcium. What is the FRAX score?  What is an easy work up we can do to rule out a secondary cause of osteoporosis before sending patient to you? The new guidelines divide patients in two categories: “High risk/no risk of fractures” and “VERY High risk/prior fractures”, What’s the difference in management between those two categories? (alendronate in high risk vs abaloparatide in very high risk). How can you tell the patient has a good response after 1 year of treatment (Dexa scan, bone turnover markers)? What is a drug holiday? ___________________________Now we conclude our episode number 45 “Osteoporosis Update”. Dr Linares explained what the FRAX score is and mentioned the different options we have for treatment of osteoporosis. DEXA scan continues to be the gold standard for screening, diagnosis and monitoring of osteoporosis. We will announce the winner of the question of the month about polyarthralgia next week, and we wish our new group of residents a great start in July 2021. Remember, even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RBresidency@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Maria Linares, and Claudia Carranza. Audio edition: Suraj Amrutia. See you next week! _____________________References:Lee S, Fu K, Kohno T, Ransford B, Maisel WH. Clinically significant magnetic interference of implanted cardiac devices by portable headphones. Heart Rhythm. 2009 Oct;6(10):1432-6. doi: 10.1016/j.hrthm.2009.07.003. Epub 2009 Jul 8. PMID: 19968922. https://www.heartrhythmjournal.com/article/S1547-5271(09)00740-1/fulltextGreenberg, Joshua C.; Mahmoud R. Altawil; Gurjit Singh; Letter to the Editor—Lifesaving Therapy Inhibition by Phones Containing Magnets, Heart Rhythm, January 04, 2021. DOI:https://doi.org/10.1016/j.hrthm.2020.12.032.  https://www.heartrhythmjournal.com/article/S1547-5271(20)31227-3/fulltext“About the magnets inside iPhone 12, iPhone 12 mini, iPhone 12 Pro, iPhone 12 Pro Max, and MagSafe accessories”, Apple Support, https://support.apple.com/en-us/HT211900, accessed on March 2, 2021. AACE Releases 2020 Clinical Practice Guidelines for Postmenopausal Osteoporosis, Physician Weekly, September 11, 2020, https://www.physiciansweekly.com/aace-releases-2020-update-clinical-practice-guidelines-for-postmenopausal-osteoporosis/

Taylor v. Medtronic, Inc.

The Dan Abrams Company v. Medtronic Inc.

Featuring: Ram Haddas, PhD of the Texas Back Institute Dr. Ram Haddas is back with another episode. This time, he has tips to help you keep your space tidy without hurting your back! Disclosure: Haddas, Ram: Grants: Aspen Medical Products Inc. (D, Paid directly to institution/employer), Medtronic Inc. (D, Paid directly to institution/employer), SI-Bone Inc. (D, Paid directly to institution/employer), The Cervical Spine Research Society (C, Paid directly to institution/employer).

Featuring: Ram Haddas, PhD of the Texas Back Institute Dr. Ram Haddas returns this episode to help you understand how Pilates can be beneficial for spine health and how you can safely try this form of exercise. Disclosure: Haddas, Ram: Grants: Aspen Medical Products Inc. (D, Paid directly to institution/employer), Medtronic Inc. (D, Paid directly to institution/employer), SI-Bone Inc. (D, Paid directly to institution/employer), The Cervical Spine Research Society (C, Paid directly to institution/employer).

Featuring: Ram Haddas, PhD of the Texas Back Institute Did you know your core muscles are a key component in spine health? Dr. Ram Haddas provides the mechanics of your core muscle region and tells you how you can engage these muscles to prevent injuries and reduce back pain. Disclosure: Haddas, Ram: Grants: Aspen Medical Products Inc. (D, Paid directly to institution/employer), Medtronic Inc. (D, Paid directly to institution/employer), SI-Bone Inc. (D, Paid directly to institution/employer), The Cervical Spine Research Society (C, Paid directly to institution/employer).

Featuring: Ram Haddas, PhD of the Texas Back Institute Dr. Ram Haddas of the Texas Back Institute explains why your phone addiction can cause neck problems and offers tips to prevent them. Disclosure: Haddas, Ram: Grants: Aspen Medical Products Inc. (D, Paid directly to institution/employer), Medtronic Inc. (D, Paid directly to institution/employer), SI-Bone Inc. (D, Paid directly to institution/employer), The Cervical Spine Research Society (C, Paid directly to institution/employer).

Featuring: Ram Haddas, PhD of the Texas Back Institute Dr. Ram Haddas of the Texas Back Institute warns of the dangers of prolonged sitting and gives you tips on how to protect your back. Disclosure: Haddas, Ram: Grants: Aspen Medical Products Inc. (D, Paid directly to institution/employer), Medtronic Inc. (D, Paid directly to institution/employer), SI-Bone Inc. (D, Paid directly to institution/employer), The Cervical Spine Research Society (C, Paid directly to institution/employer).

Richard H. Anderson served as Executive Chairman of the Delta Air Lines, Inc. Board of Directors until October 11, 2016. Richard previously served nine years as Chief Executive Officer and Board Member of Delta. Under Richard’s leadership, Delta emerged from bankruptcy and became the most profitable, investment grade airline in the world. Anderson also served as Chief Operating Officer of Northwest Airlines, Inc. from 1998 to 2001 and from 2001 to 2004, as Chief Executive Officer. Prior to joining Delta, Anderson was President of UnitedHealth Group Commercial Markets. He also serves as a director of Cargill Inc. and Medtronic Inc. A native of Galveston, Texas, Richard holds a bachelor’s degree from the University of Houston at Clear Lake City and a Juris Doctor degree from South Texas College of Law. He and his wife, Susan, live in Houston, Texas. 

Health: Is there anything more important? In this episode, we examine three bills that moved through Congress in 2016 which would have a direct effect on the health of American citizens. Would the changes benefit you? This episode is dedicated to the loving memory of Nathan Brightbill. He will be forever loved and missed. Please support Congressional Dish: Click here to contribute with PayPal or Bitcoin; click the PayPal "Make it Monthly" checkbox to create a monthly subscription Click here to support Congressional Dish for each episode via Patreon Mail Contributions to: 5753 Hwy 85 North #4576 Crestview, FL 32536 Thank you for supporting truly independent media! Bills Highlighted in this Episode H.R.3762:Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 Bill Highlights Defunds the Prevention and Public Health Fund Rescinds money for States operating their own health insurance exchanges Eliminates the last year of a temporary fee to be paid by health insurance companies to fund care for “high risk individuals” Repeals limits on out of pocket health expenses for low income families Repeals the eligibility requirements for getting health care as individuals Repeals the advance payment of tax credits to help low income people pay for their individual premiums Eliminates the small business tax credit for companies with less than 25 employees and provide health insurance for their employees Eliminates the tax penalty for people who don’t get their own health insurance Eliminates the tax penalty for large employers who don’t provide their employees health insurance and backdates it to protect large companies who didn’t provide health insurance in 2015 Cut off money to States that give money to any organization that provides abortions (Planned Parenthood) Greatly reduces the amount of money for Medicaid, which is health care for poor people Repeals the 2.3% Medical Device Tax on the manufactures of large medical equipment, even though it was suspended for two years by the omnibus Transfers over $379 billion from the Treasury to the Federal Hospital Insurance Fund, which is where our payroll taxes go and is used to fund Medicare. Congressional Budget Office Report Analysis of H.R. 3762 Restoring Americans’ Healthcare Freedom Reconciliation Act December 11, 2015 Vote Senate: 52 -47 House 240 - 181 Vetoed by President Obama Author Rep. Tom Price of Georgia’s 6th district Organizations Lobbying For H.R. 3762 Medtronic Inc.: 6 times Has more than doubled it’s lobbyist spending since 2008 - spends about $5 million per year Manufacturers expensive medical devices; the ones that have to pay a 2.3% medical device tax In 2014, gave out over a quarter million directly to members of Congress Pharmaceutical Research & Manufacturers of America: 15 times Represents drug companies and spent $18.4 million on lobbyists in 2015 America’s Health Insurance Plans: 20 times US Chamber of Commerce: 41 times Organizations Lobbying Against H.R. 3762 Planned Parenthood: 4 times H.R. 1927: Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2016 (FACT Act) Bill Highlights Federal courts would be prohibited from certifying any class action lawsuit unless every person in the lawsuit has suffered “the same type and scope of injury” as the named class representative A trust set up for a company that has gone bankrupt but still owes money to claimants has to publicly report the name and exposure history of each person and the basis of the payments to that person The information would not include their “confidential” medical record or their social security number The trust would have to provide payment information or information about payment demands from the trust if the request is about liability of asbestos exposure These disclosure requirements would be valid for all Chapter 11 cases. Vote Passed the House of Representatives: 211-188 President Obama issued a Veto threat Author Bob Goodlatte of Virginia’s 6th District Biggest contributor during his career has been the National Auto Dealers Association Organizations Lobbying For H.R. 1927: Property Casualty Insurers Association of America: 8 times US Chamber of Commerce: 6 times Honeywell International: 3 times Organizations Lobbying Against H.R. 1927: American Association for Justice: 30 times American Bar Association: 13 times H.R. 2017: Common Sense Nutrition Disclosure Act of 2015 Bill Highlights Amends disclosure requirements for chain restaurants with more than 20 locations Instead of requiring the restaurants to display "the number of calories in the standard menu item, as usually prepared and offered for sale", the restaurant would be given the choice to display: The number of calories in the whole item The number of servings and the calories per serving or The number of calories per however the restaurant chooses to divide it Restaurants where "the majority" of orders are placed by off-premises customers, the restaurant may choose to only provide nutrition information by "a remote-access menu" (such as a menu available on the Internet) as the sole method of disclosure instead of on-premises writings" Allows buffet and self-serve restaurants to publish nutrition information on the Internet instead of on a sign adjacent to each food, if they choose to. Nutrition information "shall be treated as having a reasonable basis even if such disclosures vary from actual nutrient content" Regulations for enforcing this bill will have to be created within a year. The bill then prohibits any regulations regarding nutritional information at restaurants, including regulations that have already taken affect, from taking effect until 2 years after the new regulations are done, killing all nutritional information requirement for three years. Restaurants will not have to have their nutritional information certified for accuracy. Restaurants "shall not be liable in any civil action in Federal or State court" for violating nutritional information laws. Vote Passed the House of Representatives 266-144 Author Cathy McMorris Rodgers of Washington's 5th district Organizations Lobbying For This Bill National Restaurant Association Safeway Inc. YUM! Brands Little Caesar Enterprises Domino's Pizza Sound Clip Sources Hearing: Rules Committee Hearing H.R. 712, 1155, SA to H.R. 3762, Rules Committee January 5th, 2016 Hearing: H.R. 1927, the “Fairness in Class Action Litigation Act of 2015, April 29, 2015 Commercial (YouTube): Domino's Pizza Turnaround Additional Reading Article: Ford spent $40 million to reshape asbestos science by Jim Morris, Center for Public Integrity, February 16, 2016. Article: Absestos class action bill faces hurdles by Mark Hofmann, Business Insurance, January 17, 2016. Article: Domino's Just Unveiled a Radical Pizza Delivery Car That Took 4 Years to Build by David Gianatasio, October 22, 2015. Article: Honeywell agrees to settle Jersey City chromium lawsuit for $10 million by Michelangelo Conte, The Jersey Journal, June 9, 2015. Article: Honeywell Hit With $10.9M Verdict in Asbestos Suit by Igor Kossov, Law360, June 2, 2014. Article: The Asbestos Scam, Part 2 by Joe Nocera, New York Times, January 12, 2014. United States Government Accountability Office Report: Asbestos Injury Compensation: The Role and Administration of Asbestos Trusts , September, 2011. Article: Virginia jury hands down $25M verdict in asbestos case, by Jason L. Kennedy, March 20, 2011. Article: Honeywell Says Asbestos Verdict Was More Thank It Had Disclosed by Alex Berenson, New York Times, April 18, 2002. Article: Health Industry Sees Wish List Made Into Law, Robert Pear, NYT, Dec 6, 1999. Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio) Cover Art Design by Only Child Imaginations

Au menu de ce soir : le projet de pancréas artificiel Québécois avec Ahmad Haidar, chercheur post-doctoral à l’Institut de recherches cliniques de Montréal, l'IRCM. Ahmad développe un algorithme qui mesure en temps réel le taux de sucre dans le sang des patients diabètiques et permet ainsi de leur injecter la dose exacte d'insuline requise. Avec le Dr. Rémi Rabasa-Lhoret, ils font partie des rares équipes au monde à développer un tel projet ! Musique : The Dø - A Mess like this. Crédit photo : IRCM, équipe Maladies métaboliques / Medtronic Inc.

Medtronic Inc. v. Boston Scientific Corp. | 11/05/13 | Docket #: 12-1128

A case in which the Court held that, in a patent infringement case, the burden of proof of infringement is on the patent holder.

William Hawkins, former chairman and CEO of Medtronic Inc., dishes on mergers and acquisitions, the Food & Drug Administration and healthcare reform.

Entzündungsreaktionen sind bekannte Folgen der extrakorporalen Zirkulation. Es wurde eine miniaturisierte extrakorporale Zirkulation (MEKZ) ohne Kardiotomiesauger und venöses Reservoir entwickelt, um diese Komplikationen zu verringern. Das geschlossene System mit heparinisierten Schläuchen und einer Zentrifugalpumpe sollte die Entzündungsreaktion nach aorto-koronarer Bypassoperation aufgrund eines geringeren Fremdoberflächenkontaktes reduzieren. Das Ziel dieser Studie war, Inflammationsreaktionen und Operationsergebnisse bei kardiopulmonalem Bypass zwischen einer konventionellen extrakorporalen Zirkulation (KEKZ) und der MEKZ zu vergleichen. Es wurden 30 Patienten (23% weiblich, Alter 67,9 ± 9,0 Jahre) vor einer aorto-pulmonalen Bypassoperation prospektiv randomisiert. Die EKZ wurde dann entweder konventionell oder minimal durchgeführt. Die KEKZ verwendete Rollenpumpen, einen Kardiotomiesauger sowie ein venöses Reservoir und hatte ein Primingvolumen von 1500 ml. Die MEKZ bestand aus einer Zentrifugalpumpe, einem arteriellen Filter, einem heparinisierten Schlauchsystem (Carmeda; Medtronic Inc.) und einem Oxygenator mit einem Primingvolumen von 750 ml. Abgesaugtes Blut wurde reinfundiert, nachdem es in einem Cellsaver gereinigt wurde. Als Marker für die Inflammation wurden IL-2 Rezeptor, IL-6, IL-10, TNF-α Rezeptoren p55 und p75 sowie Leukozyten und CRP an sechs verschiedenen Zeitpunkten perioperativ bestimmt. Sekundäre Zielparameter waren Intubations- und Intensivaufenthaltsdauer, Blutverlust, Fremdblut- und Katecholaminbedarf. Außer einem Herzinfarkt in der KEKZ-Gruppe kamen keine schweren Komplikationen vor. In zwei Fällen gelangte Luft in das geschlossene MEKZ-System und brachte es zum Stillstand. In einem der beiden Fälle geschah dies aufgrund anatomischen Begebenheiten und ist somit nicht vorhersehbar. Dadurch wurden die niedrigen Sicherheitsgrenzen der MEKZ aufgezeigt und die Studie vorzeitig abgebrochen. Begrenzte Entlüftungsmöglichkeiten und Schwierigkeiten des Volumen-Management in Gegenwart massiver Blutungen, erschwerten zusätzlich die Arbeit des Operateurs mit dem MEKZ System. Die statistische Analyse bei Messwertwiederholung zeigte, dass kein einziger Entzündungsparameter zwischen beiden Gruppen signifikant unterschiedlich war. Auch klinische Parameter zeigten keinerlei signifikante Unterschiede. Der Gebrauch der MEKZ beeinflusste die Entzündungsreaktion nicht signifikant und führte auch nicht zu Verbesserung klinischer Größen wie Blutverlust, Fremdblutbedarf, Intubationsdauer oder Intensivaufenthalt. Die Sicherheitsrisiken in Bezug auf Volumenmanagement und Luftembolien sind in diesem System so nicht vertretbar. Es bedarf weiterer Studien an modifizierten Systemen mit höherer Patientensicherheit, um klinische Vorteile für den herzchirurgischen Patienten klar zu erfassen.